{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:40:11Z","timestamp":1699836011696},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":11157,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1976,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Forty\u2010five children with acute nonlymphoblastic leukemia in relapse received a total of 56 courses of L\u2010asparaginase combined with vincristine and prednisone. The complete remission rate of 40% (12 of 30 trials) in patients resistant to vincristine and prednisone was almost identical to that in children still sensitive to vincristine and prednisone (42%, 11 of 26 trials). The complete remission rate of 38% (14 of 37 exposures) in those children who had not received L\u2010asparaginase previously compared favorably with the complete remission rate in those children who had received prior L\u2010asparaginase (47%, 9 of 19 exposures). Forty\u2010seven of the 56 induction trials were in children with 1 or more remissions and 14 of these were in children with 3 or more prior remissions. Toxicity was minimal.<\/jats:p>","DOI":"10.1002\/mpo.2950020209","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T14:14:24Z","timestamp":1171980864000},"page":"191-198","source":"Crossref","is-referenced-by-count":4,"title":["Remission induction with L\u2010asparaginase, vincristine, and prednisone in children with acute nonl ymphoblastic leukemia"],"prefix":"10.1002","volume":"2","author":[{"given":"Vita J.","family":"Land","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru W.","family":"Sutow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Dyment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Falletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel K.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Hugh","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1971)28:4<819::AID-CNCR2820280403>3.0.CO;2-9"},{"key":"e_1_2_1_3_2","first-page":"942","article-title":"L\u2010asparaginase in the treatment of neoplastic disease in children","volume":"31","author":"Jaffee N.","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_1_4_2","first-page":"1574","article-title":"Response to highly purified L\u2010asparaginase during therapy of acute leukemia","volume":"29","author":"Hill J. M.","year":"1969","journal-title":"Cancer Res."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(70)80023-3"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-74-6-893"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1971)28:4<825::AID-CNCR2820280404>3.0.CO;2-H"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197002)25:2<279::AID-CNCR2820250205>3.0.CO;2-7"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196911062811902"},{"key":"e_1_2_1_11_2","first-page":"2297","article-title":"Biochemical and pharmacological studies with asparaginase in man","volume":"30","author":"Ohnuma T.","year":"1970","journal-title":"Cancer Res."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197408)34:2<472::AID-CNCR2820340236>3.0.CO;2-A"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197003262821307"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5"},{"key":"e_1_2_1_15_2","unstructured":"Komp D. M. George S. L. Falletta J. M. Land V. J. Starling K. A. Humphrey G. B. andLowman J.Cyclophosphamide\u2010asparaginase\u2010vincristine\u2010prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. (In press.)"},{"key":"e_1_2_1_16_2","first-page":"169","article-title":"Response and toxicity in childhood leukemia when cyclophosphamide and L\u2010asparaginase are added to vincristine\u2010prednisone induction","volume":"15","author":"Komp D.","year":"1974","journal-title":"Proc. AACR ASCO"},{"key":"e_1_2_1_17_2","first-page":"65","article-title":"Acute myelogenous leukemia: Results of enzyme and chemotherapy","volume":"5","author":"Hill J. M.","year":"1975","journal-title":"Wadley Medical Bulletin"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<339::AID-CNCR2820300206>3.0.CO;2-P"},{"key":"e_1_2_1_19_2","first-page":"25","article-title":"Phase II study of A\u20108103 (NSC\u201025154) in acute leukemia in adults","volume":"42","author":"Hewlett J. S.","year":"1964","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","unstructured":"Tan C.L\u2010asparaginase in leukemia. Hosp. Pract.99\u2013104 July1972.","DOI":"10.1080\/21548331.1972.11706228"},{"key":"e_1_2_1_21_2","first-page":"802","article-title":"The advantage of cell synchronization in therapy of myeloid leukemias in children","volume":"38","author":"Lampkin B. C.","year":"1971","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V42.3.359.359","article-title":"5\u2010azacytidine: A new active agent for the treatment of acute leukemia","volume":"42","author":"Karon M.","year":"1973","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197204)29:4<1057::AID-CNCR2820290455>3.0.CO;2-Q"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197402)33:2<427::AID-CNCR2820330218>3.0.CO;2-8"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950020209","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950020209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T23:59:09Z","timestamp":1699833549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950020209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1976,1]]}},"alternative-id":["10.1002\/mpo.2950020209"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950020209","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1976,1]]}}}